이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ProstaLund 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Anders Kristensson

최고 경영자

SEK 2.3m

총 보상

CEO 급여 비율	17.2%
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	1.1yrs

최근 관리 업데이트

Recent updates

We Think ProstaLund (STO:PLUN) Can Afford To Drive Business Growth

May 12

CEO 보상 분석

Anders Kristensson 의 보수는 ProstaLund 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-SEK 22m
Mar 31 2024	n/a	n/a	-SEK 19m
Dec 31 2023	SEK 2m	SEK 394k	-SEK 17m

보상 대 시장: Anders 의 총 보상 ($USD 224.65K )은 Swedish 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 274.50K ).

보상과 수익: Anders 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.

CEO

Anders Kristensson (50 yo)

less than a year

테뉴어

SEK 2,291,833

보상

Mr. Anders Kristensson has been the Chief Executive Officer of ProstaLund AB (publ) since October 2023. Mr. Kristensson served as the CEO of TikoMed AB. He has several years of experience from the Pharma i...

리더십 팀

이름	위치	테뉴어	보상	소유권
Anders Kristensson	Chief Executive Officer	less than a year	SEK 2.29m	데이터 없음
Niclas Nystroom	Chief Financial Officer	less than a year	데이터 없음	데이터 없음
Erika Carlsson	Chief Operating Officer	2.7yrs	데이터 없음	0% SEK 0
Johan Laven	Director of Sales & Marketing	less than a year	데이터 없음	데이터 없음
Charlotta Andersson	Sales Manager and Clinical Instructor - Sweden & Finland	no data	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

50.5yo

평균 연령

경험이 풍부한 관리: PLUN 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Paul de Potocki	Independent Director	less than a year	SEK 20.13k	데이터 없음
Marianne Ostlund	Independent Director	4.7yrs	SEK 96.60k	0.076% SEK 37.4k
Sonny Schelin	Director	12.7yrs	SEK 76.48k	0.058% SEK 28.4k
Tomas Eriksson	Independent Director	less than a year	SEK 20.13k	데이터 없음
Annette Colin	Independent Director	1.3yrs	SEK 64.40k	데이터 없음
Lars Johansson	Independent Director	2.3yrs	SEK 142.89k	0% SEK 0
Per Langoo	Independent Chairman	less than a year	SEK 50.31k	데이터 없음
Tom Roonnlund	Independent Director	less than a year	SEK 20.13k	데이터 없음

1.1yrs

평균 재임 기간

59.5yo

평균 연령

경험이 풍부한 이사회: PLUN 의 이사회는 경험(평균 재직 기간 1.1 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

ProstaLund 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

High number of new directors

ProstaLund AB (publ), Annual General Meeting, May 30, 2024

Director recently bought kr98k worth of stock

Director recently bought kr81k worth of stock

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

High number of new directors

Second quarter 2024 earnings released: kr0.094 loss per share (vs kr0.065 loss in 2Q 2023)

New major risk - Shareholder dilution

First quarter 2024 earnings released: kr0.062 loss per share (vs kr0.056 loss in 1Q 2023)

Full year 2023 earnings released: kr0.25 loss per share (vs kr0.21 loss in FY 2022)

ProstaLund AB (publ), Annual General Meeting, May 30, 2024

New major risk - Financial position

Third quarter 2023 earnings released: kr0.082 loss per share (vs kr0.04 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.065 loss per share (vs kr0.072 loss in 2Q 2022)

Director recently bought kr98k worth of stock

ProstaLund AB (publ) Decides to Withdraw its 510(k) Application and Intend Instead to Submit a De Novo Application for Schelin Catheter® in the US

Prostalund AB (Publ) Announces Successfully Used At Asst Grande Ospedale Metropolitano Niguarda

First quarter 2023 earnings released: kr0.056 loss per share (vs kr0.042 loss in 1Q 2022)

Full year 2022 earnings released: kr0.21 loss per share (vs kr0.17 loss in FY 2021)

Director recently bought kr81k worth of stock

ProstaLund AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024

ProstaLund Receives CE Approval Under MDR for its New Treatment Platform Coretherm® Eagle

High number of new and inexperienced directors

ProstaLund Files its 510(k) Application to the FDA for the Schelin Catheter

High number of new and inexperienced directors

Prostalund AB (Publ) Announces Coreflow® - Soft Stent - First Patient in the Uk Under Treatment

Insider recently bought kr229k worth of stock

Less than half of directors are independent

We Think ProstaLund (STO:PLUN) Can Afford To Drive Business Growth

Full year 2021 earnings released

ProstaLund Successfully Introduces Schelin Catheter as Tool

ProstaLund AB (publ) to Report Q1, 2022 Results on May 11, 2022

ProstaLund AB (publ), Annual General Meeting, May 05, 2022

ProstaLund AB (publ) Receives Utility Patent in China

Second quarter 2021 earnings released: kr0.066 loss per share (vs kr0.096 loss in 2Q 2020)

Chief Financial Officer exercised options to buy kr461k worth of stock.

Chief Financial Officer exercised options to buy kr453k worth of stock.

Prostalund Signs A Four-Year Framework Agreement with the Västra Götaland Region

New 90-day high: kr5.90

Third quarter earnings released

New 90-day high: kr3.11

New 90-day high - kr2.58

First half earnings released

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령